2026-01-22 - Analysis Report
# Financial Report for Intuitive Surgical (ISRG)

## 1. Return Rate Comparison
- **Cumulative Return (ISRG)**: 66.40%
- **Cumulative Return (S&P 500, VOO)**: 91.55%
- **Divergence**: -23.30%
- **Relative Divergence**: 20.10%

**Analysis**: Intuitive Surgical's return rate lags behind the S&P 500 by 23.30%, indicating a significant underperformance relative to the broader market.

## Alpha, Beta Analysis
| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B)  |
|------------|--------|-------|--------|------|---------|
| 2016-2018  | 49.0%  | 29.0% | 44.0%  | 1.2  | 57.2B   |
| 2017-2019  | 40.0%  | 29.0% | 23.0%  | 1.4  | 70.6B   |
| 2018-2020  | -8.0%  | 29.0% | -29.0% | 1.2  | 97.8B   |
| 2019-2021  | 26.0%  | 21.1% | -18.0% | 1.2  | 128.8B  |
| 2020-2022  | -18.0% | 48.9% | -16.0% | 1.2  | 95.1B   |
| 2021-2023  | -12.0% | 48.9% | -13.0% | 1.4  | 120.9B  |
| 2022-2024  | 35.0%  | 38.0% | 16.0%  | 1.3  | 187.1B  |
| 2023-2025  | 60.0%  | 28.0% | -2.0%  | 1.2  | 203.0B  |

**Analysis**: The CAGR over the recent periods shows volatility, with a notable decline in returns during 2018-2020. The latest periods exhibit recovery with a 60% CAGR projected for 2023-2025.

## 2. Recent Stock Price Fluctuations
- **Current Close Price**: $523.69
- **Previous Close**: $527.44
- **Change**: -$0.71
- **5-Day SMA**: $534.85
- **20-Day SMA**: $566.01
- **60-Day SMA**: $560.53

**Analysis**: The stock price has recently declined, below all moving averages, indicating possible weakness in price momentum.

## 3. RSI and PPO Indicators
- **Market Risk Indicator (MRI)**: 0.80 (Medium Investment)
- **RSI**: 28.35 (Oversold)
- **PPO**: -1.24
- **Hybrid Signal**: Buy (Cash 0%)
- **Recent Relative Divergence Change**: -12.90 (worsening)
- **7-Day Rank Change**: +30 (rank up)
- **7-Day Dynamic Expected Return Change**: +1.10 (improving)
- **Expected Return**: 8.30% 

**Analysis**: The RSI indicates the stock is oversold, while the MRI suggests medium investment risk. The expected return is positive, albeit with declining relative divergence.

## 4. Recent News & Significant Events
- **Assessing Whether Intuitive Surgical Shares Look Overvalued After Recent Weak Price Performance**
- **ISRG vs. MDT: Which MedTech Stock Is a Better Bet Now?**
- **AI drives outlook for ISRG**
- **Intuitive Surgical continues losses for seven straight sessions**
- **Q4 2025 Earnings Preview**

**Analysis**: Recent news highlights concerns regarding the valuation of ISRG shares amid ongoing losses, which may impact investor sentiment.

## 4-2. Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.06 (~Buy)
- Opinions: 29
- Target Price (avg/high/low): 608.26 / 740.00 / 378.00
```

## 5. Recent Earnings Analysis
| Date       | EPS  | Revenue  |
|------------|------|----------|
| 2025-10-22 | 1.98 | 2.51 B$  |
| 2025-07-23 | 1.84 | 2.44 B$  |
| 2025-04-23 | 1.95 | 2.25 B$  |
| 2024-10-18 | 1.59 | 2.04 B$  |
| 2025-10-22 | 1.59 | 2.04 B$  |

**Analysis**: The EPS has shown variability, with a notable increase to 1.98 in the latest quarter. Revenue has been steadily above $2 billion, indicating solid sales performance.

## 6. Financial Information
### Revenue and Profitability
| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $2.51B  | 66.36%        |
| 2025-06-30   | $2.44B  | 66.31%        |
| 2025-03-31   | $2.25B  | 64.69%        |
| 2024-12-31   | $2.41B  | 68.04%        |
| 2024-09-30   | $2.04B  | 67.41%        |

### Capital and Profitability
| Quarter      | Equity  | ROE   |
|--------------|---------|-------|
| 2025-09-30   | $16.93B | 4.16% |
| 2025-06-30   | $17.85B | 3.69% |
| 2025-03-31   | $17.11B | 4.08% |
| 2024-12-31   | $16.43B | 4.17% |
| 2024-09-30   | $15.58B | 3.63% |

**Analysis**: Revenue growth is consistent, with profit margins stabilizing around 66%. ROE has shown slight fluctuations but remains positive.

## 7. Comprehensive Analysis
Intuitive Surgical has shown strong revenue growth and a favorable analyst consensus, despite recent underperformance compared to the S&P 500. Key indicators such as RSI suggest a potential recovery phase, though current sentiment is affected by recent losses and market concerns. Analyst targets indicate potential upside, while financials remain robust with solid revenue and profitability metrics.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.